The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Targeted Drugs for Multiple Myeloma Market Research Report 2025
Synopsis
The global Targeted Drugs for Multiple Myeloma market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Targeted Drugs for Multiple Myeloma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Drugs for Multiple Myeloma.
Report Scope
The Targeted Drugs for Multiple Myeloma market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Targeted Drugs for Multiple Myeloma market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Targeted Drugs for Multiple Myeloma companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Celgene
Exova
Natco Pharma
Intas Pharmaceuticals
Indiabulls Pharmaceutical
Cipla
Glenmark Pharmaceuticals
Dr Reddy's Laboratories
Qilu Pharmaceutical
Chia Tai-Tianqing
Hanson Pharm
Meidakang Huakang Pharmaceutical
Shandong Kongfu Pharmaceutical
J&J
Takeda
Amgen
Bristol Myers Squibb
Abbvie
Seattle Genetics
Karyopharm Therapeutics
PDL BioPharma
Roche
Sumitomo
Merck
Biogen
Schering-Plough
Glaxo
Chiron
Segment by Type
Immunomodulator
Proteasome Inhibitors
Histone Deacetylase Inhibitors (HDACI)
Monoclonal Antibody
Others
Segment by Application
Hospital
Drug Center
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Targeted Drugs for Multiple Myeloma companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Targeted Drugs for Multiple Myeloma market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Targeted Drugs for Multiple Myeloma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Drugs for Multiple Myeloma.
Report Scope
The Targeted Drugs for Multiple Myeloma market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Targeted Drugs for Multiple Myeloma market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Targeted Drugs for Multiple Myeloma companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Celgene
Exova
Natco Pharma
Intas Pharmaceuticals
Indiabulls Pharmaceutical
Cipla
Glenmark Pharmaceuticals
Dr Reddy's Laboratories
Qilu Pharmaceutical
Chia Tai-Tianqing
Hanson Pharm
Meidakang Huakang Pharmaceutical
Shandong Kongfu Pharmaceutical
J&J
Takeda
Amgen
Bristol Myers Squibb
Abbvie
Seattle Genetics
Karyopharm Therapeutics
PDL BioPharma
Roche
Sumitomo
Merck
Biogen
Schering-Plough
Glaxo
Chiron
Segment by Type
Immunomodulator
Proteasome Inhibitors
Histone Deacetylase Inhibitors (HDACI)
Monoclonal Antibody
Others
Segment by Application
Hospital
Drug Center
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Targeted Drugs for Multiple Myeloma companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Immunomodulator
1.2.3 Proteasome Inhibitors
1.2.4 Histone Deacetylase Inhibitors (HDACI)
1.2.5 Monoclonal Antibody
1.2.6 Others
1.3 Market by Application
1.3.1 Global Targeted Drugs for Multiple Myeloma Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Drug Center
1.3.4 Clinic
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Targeted Drugs for Multiple Myeloma Market Perspective (2019-2030)
2.2 Targeted Drugs for Multiple Myeloma Growth Trends by Region
2.2.1 Global Targeted Drugs for Multiple Myeloma Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Targeted Drugs for Multiple Myeloma Historic Market Size by Region (2019-2024)
2.2.3 Targeted Drugs for Multiple Myeloma Forecasted Market Size by Region (2025-2030)
2.3 Targeted Drugs for Multiple Myeloma Market Dynamics
2.3.1 Targeted Drugs for Multiple Myeloma Industry Trends
2.3.2 Targeted Drugs for Multiple Myeloma Market Drivers
2.3.3 Targeted Drugs for Multiple Myeloma Market Challenges
2.3.4 Targeted Drugs for Multiple Myeloma Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Targeted Drugs for Multiple Myeloma Players by Revenue
3.1.1 Global Top Targeted Drugs for Multiple Myeloma Players by Revenue (2019-2024)
3.1.2 Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Players (2019-2024)
3.2 Global Targeted Drugs for Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Targeted Drugs for Multiple Myeloma Revenue
3.4 Global Targeted Drugs for Multiple Myeloma Market Concentration Ratio
3.4.1 Global Targeted Drugs for Multiple Myeloma Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Targeted Drugs for Multiple Myeloma Revenue in 2023
3.5 Targeted Drugs for Multiple Myeloma Key Players Head office and Area Served
3.6 Key Players Targeted Drugs for Multiple Myeloma Product Solution and Service
3.7 Date of Enter into Targeted Drugs for Multiple Myeloma Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Targeted Drugs for Multiple Myeloma Breakdown Data by Type
4.1 Global Targeted Drugs for Multiple Myeloma Historic Market Size by Type (2019-2024)
4.2 Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Type (2025-2030)
5 Targeted Drugs for Multiple Myeloma Breakdown Data by Application
5.1 Global Targeted Drugs for Multiple Myeloma Historic Market Size by Application (2019-2024)
5.2 Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Targeted Drugs for Multiple Myeloma Market Size (2019-2030)
6.2 North America Targeted Drugs for Multiple Myeloma Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Targeted Drugs for Multiple Myeloma Market Size by Country (2019-2024)
6.4 North America Targeted Drugs for Multiple Myeloma Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Targeted Drugs for Multiple Myeloma Market Size (2019-2030)
7.2 Europe Targeted Drugs for Multiple Myeloma Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Targeted Drugs for Multiple Myeloma Market Size by Country (2019-2024)
7.4 Europe Targeted Drugs for Multiple Myeloma Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size (2019-2030)
8.2 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size by Region (2019-2024)
8.4 Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Targeted Drugs for Multiple Myeloma Market Size (2019-2030)
9.2 Latin America Targeted Drugs for Multiple Myeloma Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Targeted Drugs for Multiple Myeloma Market Size by Country (2019-2024)
9.4 Latin America Targeted Drugs for Multiple Myeloma Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size (2019-2030)
10.2 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Country (2019-2024)
10.4 Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Celgene
11.1.1 Celgene Company Detail
11.1.2 Celgene Business Overview
11.1.3 Celgene Targeted Drugs for Multiple Myeloma Introduction
11.1.4 Celgene Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.1.5 Celgene Recent Development
11.2 Exova
11.2.1 Exova Company Detail
11.2.2 Exova Business Overview
11.2.3 Exova Targeted Drugs for Multiple Myeloma Introduction
11.2.4 Exova Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.2.5 Exova Recent Development
11.3 Natco Pharma
11.3.1 Natco Pharma Company Detail
11.3.2 Natco Pharma Business Overview
11.3.3 Natco Pharma Targeted Drugs for Multiple Myeloma Introduction
11.3.4 Natco Pharma Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.3.5 Natco Pharma Recent Development
11.4 Intas Pharmaceuticals
11.4.1 Intas Pharmaceuticals Company Detail
11.4.2 Intas Pharmaceuticals Business Overview
11.4.3 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Introduction
11.4.4 Intas Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.4.5 Intas Pharmaceuticals Recent Development
11.5 Indiabulls Pharmaceutical
11.5.1 Indiabulls Pharmaceutical Company Detail
11.5.2 Indiabulls Pharmaceutical Business Overview
11.5.3 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
11.5.4 Indiabulls Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.5.5 Indiabulls Pharmaceutical Recent Development
11.6 Cipla
11.6.1 Cipla Company Detail
11.6.2 Cipla Business Overview
11.6.3 Cipla Targeted Drugs for Multiple Myeloma Introduction
11.6.4 Cipla Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.6.5 Cipla Recent Development
11.7 Glenmark Pharmaceuticals
11.7.1 Glenmark Pharmaceuticals Company Detail
11.7.2 Glenmark Pharmaceuticals Business Overview
11.7.3 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Introduction
11.7.4 Glenmark Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.7.5 Glenmark Pharmaceuticals Recent Development
11.8 Dr Reddy's Laboratories
11.8.1 Dr Reddy's Laboratories Company Detail
11.8.2 Dr Reddy's Laboratories Business Overview
11.8.3 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Introduction
11.8.4 Dr Reddy's Laboratories Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.8.5 Dr Reddy's Laboratories Recent Development
11.9 Qilu Pharmaceutical
11.9.1 Qilu Pharmaceutical Company Detail
11.9.2 Qilu Pharmaceutical Business Overview
11.9.3 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
11.9.4 Qilu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.9.5 Qilu Pharmaceutical Recent Development
11.10 Chia Tai-Tianqing
11.10.1 Chia Tai-Tianqing Company Detail
11.10.2 Chia Tai-Tianqing Business Overview
11.10.3 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Introduction
11.10.4 Chia Tai-Tianqing Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.10.5 Chia Tai-Tianqing Recent Development
11.11 Hanson Pharm
11.11.1 Hanson Pharm Company Detail
11.11.2 Hanson Pharm Business Overview
11.11.3 Hanson Pharm Targeted Drugs for Multiple Myeloma Introduction
11.11.4 Hanson Pharm Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.11.5 Hanson Pharm Recent Development
11.12 Meidakang Huakang Pharmaceutical
11.12.1 Meidakang Huakang Pharmaceutical Company Detail
11.12.2 Meidakang Huakang Pharmaceutical Business Overview
11.12.3 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
11.12.4 Meidakang Huakang Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.12.5 Meidakang Huakang Pharmaceutical Recent Development
11.13 Shandong Kongfu Pharmaceutical
11.13.1 Shandong Kongfu Pharmaceutical Company Detail
11.13.2 Shandong Kongfu Pharmaceutical Business Overview
11.13.3 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
11.13.4 Shandong Kongfu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.13.5 Shandong Kongfu Pharmaceutical Recent Development
11.14 J&J
11.14.1 J&J Company Detail
11.14.2 J&J Business Overview
11.14.3 J&J Targeted Drugs for Multiple Myeloma Introduction
11.14.4 J&J Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.14.5 J&J Recent Development
11.15 Takeda
11.15.1 Takeda Company Detail
11.15.2 Takeda Business Overview
11.15.3 Takeda Targeted Drugs for Multiple Myeloma Introduction
11.15.4 Takeda Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.15.5 Takeda Recent Development
11.16 Amgen
11.16.1 Amgen Company Detail
11.16.2 Amgen Business Overview
11.16.3 Amgen Targeted Drugs for Multiple Myeloma Introduction
11.16.4 Amgen Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.16.5 Amgen Recent Development
11.17 Bristol Myers Squibb
11.17.1 Bristol Myers Squibb Company Detail
11.17.2 Bristol Myers Squibb Business Overview
11.17.3 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Introduction
11.17.4 Bristol Myers Squibb Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.17.5 Bristol Myers Squibb Recent Development
11.18 Abbvie
11.18.1 Abbvie Company Detail
11.18.2 Abbvie Business Overview
11.18.3 Abbvie Targeted Drugs for Multiple Myeloma Introduction
11.18.4 Abbvie Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.18.5 Abbvie Recent Development
11.19 Seattle Genetics
11.19.1 Seattle Genetics Company Detail
11.19.2 Seattle Genetics Business Overview
11.19.3 Seattle Genetics Targeted Drugs for Multiple Myeloma Introduction
11.19.4 Seattle Genetics Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.19.5 Seattle Genetics Recent Development
11.20 Karyopharm Therapeutics
11.20.1 Karyopharm Therapeutics Company Detail
11.20.2 Karyopharm Therapeutics Business Overview
11.20.3 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Introduction
11.20.4 Karyopharm Therapeutics Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.20.5 Karyopharm Therapeutics Recent Development
11.21 PDL BioPharma
11.21.1 PDL BioPharma Company Detail
11.21.2 PDL BioPharma Business Overview
11.21.3 PDL BioPharma Targeted Drugs for Multiple Myeloma Introduction
11.21.4 PDL BioPharma Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.21.5 PDL BioPharma Recent Development
11.22 Roche
11.22.1 Roche Company Detail
11.22.2 Roche Business Overview
11.22.3 Roche Targeted Drugs for Multiple Myeloma Introduction
11.22.4 Roche Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.22.5 Roche Recent Development
11.23 Sumitomo
11.23.1 Sumitomo Company Detail
11.23.2 Sumitomo Business Overview
11.23.3 Sumitomo Targeted Drugs for Multiple Myeloma Introduction
11.23.4 Sumitomo Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.23.5 Sumitomo Recent Development
11.24 Merck
11.24.1 Merck Company Detail
11.24.2 Merck Business Overview
11.24.3 Merck Targeted Drugs for Multiple Myeloma Introduction
11.24.4 Merck Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.24.5 Merck Recent Development
11.25 Biogen
11.25.1 Biogen Company Detail
11.25.2 Biogen Business Overview
11.25.3 Biogen Targeted Drugs for Multiple Myeloma Introduction
11.25.4 Biogen Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.25.5 Biogen Recent Development
11.26 Schering-Plough
11.26.1 Schering-Plough Company Detail
11.26.2 Schering-Plough Business Overview
11.26.3 Schering-Plough Targeted Drugs for Multiple Myeloma Introduction
11.26.4 Schering-Plough Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.26.5 Schering-Plough Recent Development
11.27 Glaxo
11.27.1 Glaxo Company Detail
11.27.2 Glaxo Business Overview
11.27.3 Glaxo Targeted Drugs for Multiple Myeloma Introduction
11.27.4 Glaxo Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.27.5 Glaxo Recent Development
11.28 Chiron
11.28.1 Chiron Company Detail
11.28.2 Chiron Business Overview
11.28.3 Chiron Targeted Drugs for Multiple Myeloma Introduction
11.28.4 Chiron Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024)
11.28.5 Chiron Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Immunomodulator
Table 3. Key Players of Proteasome Inhibitors
Table 4. Key Players of Histone Deacetylase Inhibitors (HDACI)
Table 5. Key Players of Monoclonal Antibody
Table 6. Key Players of Others
Table 7. Global Targeted Drugs for Multiple Myeloma Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Targeted Drugs for Multiple Myeloma Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Targeted Drugs for Multiple Myeloma Market Size by Region (2019-2024) & (US$ Million)
Table 10. Global Targeted Drugs for Multiple Myeloma Market Share by Region (2019-2024)
Table 11. Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 12. Global Targeted Drugs for Multiple Myeloma Market Share by Region (2025-2030)
Table 13. Targeted Drugs for Multiple Myeloma Market Trends
Table 14. Targeted Drugs for Multiple Myeloma Market Drivers
Table 15. Targeted Drugs for Multiple Myeloma Market Challenges
Table 16. Targeted Drugs for Multiple Myeloma Market Restraints
Table 17. Global Targeted Drugs for Multiple Myeloma Revenue by Players (2019-2024) & (US$ Million)
Table 18. Global Targeted Drugs for Multiple Myeloma Market Share by Players (2019-2024)
Table 19. Global Top Targeted Drugs for Multiple Myeloma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Multiple Myeloma as of 2023)
Table 20. Ranking of Global Top Targeted Drugs for Multiple Myeloma Companies by Revenue (US$ Million) in 2023
Table 21. Global 5 Largest Players Market Share by Targeted Drugs for Multiple Myeloma Revenue (CR5 and HHI) & (2019-2024)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Targeted Drugs for Multiple Myeloma Product Solution and Service
Table 24. Date of Enter into Targeted Drugs for Multiple Myeloma Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Targeted Drugs for Multiple Myeloma Market Size by Type (2019-2024) & (US$ Million)
Table 27. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Type (2019-2024)
Table 28. Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 29. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Type (2025-2030)
Table 30. Global Targeted Drugs for Multiple Myeloma Market Size by Application (2019-2024) & (US$ Million)
Table 31. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Application (2019-2024)
Table 32. Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 33. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Application (2025-2030)
Table 34. North America Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. North America Targeted Drugs for Multiple Myeloma Market Size by Country (2019-2024) & (US$ Million)
Table 36. North America Targeted Drugs for Multiple Myeloma Market Size by Country (2025-2030) & (US$ Million)
Table 37. Europe Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 38. Europe Targeted Drugs for Multiple Myeloma Market Size by Country (2019-2024) & (US$ Million)
Table 39. Europe Targeted Drugs for Multiple Myeloma Market Size by Country (2025-2030) & (US$ Million)
Table 40. Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 41. Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size by Region (2019-2024) & (US$ Million)
Table 42. Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size by Region (2025-2030) & (US$ Million)
Table 43. Latin America Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Latin America Targeted Drugs for Multiple Myeloma Market Size by Country (2019-2024) & (US$ Million)
Table 45. Latin America Targeted Drugs for Multiple Myeloma Market Size by Country (2025-2030) & (US$ Million)
Table 46. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 47. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Country (2019-2024) & (US$ Million)
Table 48. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size by Country (2025-2030) & (US$ Million)
Table 49. Celgene Company Detail
Table 50. Celgene Business Overview
Table 51. Celgene Targeted Drugs for Multiple Myeloma Product
Table 52. Celgene Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 53. Celgene Recent Development
Table 54. Exova Company Detail
Table 55. Exova Business Overview
Table 56. Exova Targeted Drugs for Multiple Myeloma Product
Table 57. Exova Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 58. Exova Recent Development
Table 59. Natco Pharma Company Detail
Table 60. Natco Pharma Business Overview
Table 61. Natco Pharma Targeted Drugs for Multiple Myeloma Product
Table 62. Natco Pharma Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 63. Natco Pharma Recent Development
Table 64. Intas Pharmaceuticals Company Detail
Table 65. Intas Pharmaceuticals Business Overview
Table 66. Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Product
Table 67. Intas Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 68. Intas Pharmaceuticals Recent Development
Table 69. Indiabulls Pharmaceutical Company Detail
Table 70. Indiabulls Pharmaceutical Business Overview
Table 71. Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Product
Table 72. Indiabulls Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 73. Indiabulls Pharmaceutical Recent Development
Table 74. Cipla Company Detail
Table 75. Cipla Business Overview
Table 76. Cipla Targeted Drugs for Multiple Myeloma Product
Table 77. Cipla Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 78. Cipla Recent Development
Table 79. Glenmark Pharmaceuticals Company Detail
Table 80. Glenmark Pharmaceuticals Business Overview
Table 81. Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Product
Table 82. Glenmark Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 83. Glenmark Pharmaceuticals Recent Development
Table 84. Dr Reddy's Laboratories Company Detail
Table 85. Dr Reddy's Laboratories Business Overview
Table 86. Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Product
Table 87. Dr Reddy's Laboratories Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 88. Dr Reddy's Laboratories Recent Development
Table 89. Qilu Pharmaceutical Company Detail
Table 90. Qilu Pharmaceutical Business Overview
Table 91. Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Product
Table 92. Qilu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 93. Qilu Pharmaceutical Recent Development
Table 94. Chia Tai-Tianqing Company Detail
Table 95. Chia Tai-Tianqing Business Overview
Table 96. Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Product
Table 97. Chia Tai-Tianqing Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 98. Chia Tai-Tianqing Recent Development
Table 99. Hanson Pharm Company Detail
Table 100. Hanson Pharm Business Overview
Table 101. Hanson Pharm Targeted Drugs for Multiple Myeloma Product
Table 102. Hanson Pharm Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 103. Hanson Pharm Recent Development
Table 104. Meidakang Huakang Pharmaceutical Company Detail
Table 105. Meidakang Huakang Pharmaceutical Business Overview
Table 106. Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Product
Table 107. Meidakang Huakang Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 108. Meidakang Huakang Pharmaceutical Recent Development
Table 109. Shandong Kongfu Pharmaceutical Company Detail
Table 110. Shandong Kongfu Pharmaceutical Business Overview
Table 111. Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Product
Table 112. Shandong Kongfu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 113. Shandong Kongfu Pharmaceutical Recent Development
Table 114. J&J Company Detail
Table 115. J&J Business Overview
Table 116. J&J Targeted Drugs for Multiple Myeloma Product
Table 117. J&J Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 118. J&J Recent Development
Table 119. Takeda Company Detail
Table 120. Takeda Business Overview
Table 121. Takeda Targeted Drugs for Multiple Myeloma Product
Table 122. Takeda Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 123. Takeda Recent Development
Table 124. Amgen Company Detail
Table 125. Amgen Business Overview
Table 126. Amgen Targeted Drugs for Multiple Myeloma Product
Table 127. Amgen Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 128. Amgen Recent Development
Table 129. Bristol Myers Squibb Company Detail
Table 130. Bristol Myers Squibb Business Overview
Table 131. Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Product
Table 132. Bristol Myers Squibb Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 133. Bristol Myers Squibb Recent Development
Table 134. Abbvie Company Detail
Table 135. Abbvie Business Overview
Table 136. Abbvie Targeted Drugs for Multiple Myeloma Product
Table 137. Abbvie Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 138. Abbvie Recent Development
Table 139. Seattle Genetics Company Detail
Table 140. Seattle Genetics Business Overview
Table 141. Seattle Genetics Targeted Drugs for Multiple Myeloma Product
Table 142. Seattle Genetics Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 143. Seattle Genetics Recent Development
Table 144. Karyopharm Therapeutics Company Detail
Table 145. Karyopharm Therapeutics Business Overview
Table 146. Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Product
Table 147. Karyopharm Therapeutics Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 148. Karyopharm Therapeutics Recent Development
Table 149. PDL BioPharma Company Detail
Table 150. PDL BioPharma Business Overview
Table 151. PDL BioPharma Targeted Drugs for Multiple Myeloma Product
Table 152. PDL BioPharma Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 153. PDL BioPharma Recent Development
Table 154. Roche Company Detail
Table 155. Roche Business Overview
Table 156. Roche Targeted Drugs for Multiple Myeloma Product
Table 157. Roche Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 158. Roche Recent Development
Table 159. Sumitomo Company Detail
Table 160. Sumitomo Business Overview
Table 161. Sumitomo Targeted Drugs for Multiple Myeloma Product
Table 162. Sumitomo Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 163. Sumitomo Recent Development
Table 164. Merck Company Detail
Table 165. Merck Business Overview
Table 166. Merck Targeted Drugs for Multiple Myeloma Product
Table 167. Merck Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 168. Merck Recent Development
Table 169. Biogen Company Detail
Table 170. Biogen Business Overview
Table 171. Biogen Targeted Drugs for Multiple Myeloma Product
Table 172. Biogen Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 173. Biogen Recent Development
Table 174. Schering-Plough Company Detail
Table 175. Schering-Plough Business Overview
Table 176. Schering-Plough Targeted Drugs for Multiple Myeloma Product
Table 177. Schering-Plough Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 178. Schering-Plough Recent Development
Table 179. Glaxo Company Detail
Table 180. Glaxo Business Overview
Table 181. Glaxo Targeted Drugs for Multiple Myeloma Product
Table 182. Glaxo Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 183. Glaxo Recent Development
Table 184. Chiron Company Detail
Table 185. Chiron Business Overview
Table 186. Chiron Targeted Drugs for Multiple Myeloma Product
Table 187. Chiron Revenue in Targeted Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 188. Chiron Recent Development
Table 189. Research Programs/Design for This Report
Table 190. Key Data Information from Secondary Sources
Table 191. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Targeted Drugs for Multiple Myeloma Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Targeted Drugs for Multiple Myeloma Market Share by Type: 2023 VS 2030
Figure 3. Immunomodulator Features
Figure 4. Proteasome Inhibitors Features
Figure 5. Histone Deacetylase Inhibitors (HDACI) Features
Figure 6. Monoclonal Antibody Features
Figure 7. Others Features
Figure 8. Global Targeted Drugs for Multiple Myeloma Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Targeted Drugs for Multiple Myeloma Market Share by Application: 2023 VS 2030
Figure 10. Hospital Case Studies
Figure 11. Drug Center Case Studies
Figure 12. Clinic Case Studies
Figure 13. Others Case Studies
Figure 14. Targeted Drugs for Multiple Myeloma Report Years Considered
Figure 15. Global Targeted Drugs for Multiple Myeloma Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 16. Global Targeted Drugs for Multiple Myeloma Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 17. Global Targeted Drugs for Multiple Myeloma Market Share by Region: 2023 VS 2030
Figure 18. Global Targeted Drugs for Multiple Myeloma Market Share by Players in 2023
Figure 19. Global Top Targeted Drugs for Multiple Myeloma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Multiple Myeloma as of 2023)
Figure 20. The Top 10 and 5 Players Market Share by Targeted Drugs for Multiple Myeloma Revenue in 2023
Figure 21. North America Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. North America Targeted Drugs for Multiple Myeloma Market Share by Country (2019-2030)
Figure 23. United States Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Canada Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Targeted Drugs for Multiple Myeloma Market Share by Country (2019-2030)
Figure 27. Germany Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. France Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. U.K. Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Italy Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Russia Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Nordic Countries Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Targeted Drugs for Multiple Myeloma Market Share by Region (2019-2030)
Figure 35. China Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Japan Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. South Korea Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Southeast Asia Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. India Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Australia Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Targeted Drugs for Multiple Myeloma Market Share by Country (2019-2030)
Figure 43. Mexico Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Brazil Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Targeted Drugs for Multiple Myeloma Market Share by Country (2019-2030)
Figure 47. Turkey Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Saudi Arabia Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Celgene Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 50. Exova Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 51. Natco Pharma Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 52. Intas Pharmaceuticals Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 53. Indiabulls Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 54. Cipla Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 55. Glenmark Pharmaceuticals Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 56. Dr Reddy's Laboratories Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 57. Qilu Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 58. Chia Tai-Tianqing Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 59. Hanson Pharm Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 60. Meidakang Huakang Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 61. Shandong Kongfu Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 62. J&J Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 63. Takeda Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 64. Amgen Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 65. Bristol Myers Squibb Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 66. Abbvie Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 67. Seattle Genetics Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 68. Karyopharm Therapeutics Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 69. PDL BioPharma Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 70. Roche Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 71. Sumitomo Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 72. Merck Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 73. Biogen Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 74. Schering-Plough Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 75. Glaxo Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 76. Chiron Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2019-2024)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
